Elicio Therapeutics (ELTX) Stock Price, News & Analysis

Company Overview

Elicio Therapeutics, Inc. is a clinical-stage biotechnology company developing immunotherapies designed to treat cancer by directing immune responses to the lymph nodes, where key immune cells are activated. The company’s technology is based on its Amphiphile platform, which is intended to improve the delivery and activity of therapeutic vaccines and other immune-modulating agents.

Elicio’s lead program is ELI-002, an investigational therapeutic cancer vaccine designed to target common KRAS mutations. The program is being evaluated in patients with KRAS-mutated solid tumors, including pancreatic and colorectal cancers. ELI-002 is intended to stimulate T-cell responses against residual disease and tumor cells carrying these mutations.

The company is also advancing additional vaccine-based immunotherapies aimed at cancer-associated targets and personalized tumor antigens. Elicio Therapeutics was formerly known as Vedantra Pharmaceuticals and has focused on developing therapies intended to harness the immune system against cancer. Its products remain investigational and are not approved for commercial use.

Key Stats

• Today's Range: $1.76 to $1.86
• 50-Day Range: $1.77 to $3.19
• 52-Week Range: $1.71 to $16.00
• Volume: 169,351 shs
• Average Volume: 299,946 shs
• Market Capitalization: $48.22 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $15.00
• Consensus Rating: Moderate Buy

Elicio Therapeutics Stock Analysis - MarketRank™

Elicio Therapeutics scored higher than 62% of companies evaluated by MarketBeat, and ranked 300th out of 870 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.9 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Elicio Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 4 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Elicio Therapeutics has a consensus price target of $15.00, representing about 742.7% upside from its current price of $1.78.

Amount of Analyst Coverage

Elicio Therapeutics has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Elicio Therapeutics are expected to grow in the coming year, from ($1.90) to ($1.74) per share.

Price to Book Value per Share Ratio

Elicio Therapeutics has a P/B Ratio of 19.78. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

12.03% of the float of Elicio Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Elicio Therapeutics has a short interest ratio ("days to cover") of 4.12.

Change versus previous month

Short interest in Elicio Therapeutics has recently decreased by 6.83%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Elicio Therapeutics does not currently pay a dividend.

Dividend Growth

Elicio Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 3.1 / 5
• News Sentiment: 0.89

News Sentiment

Elicio Therapeutics has a news sentiment score of 0.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.73 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Elicio Therapeutics this week, compared to 2 articles on an average week.

Search Interest

5 people have searched for ELTX on MarketBeat in the last 30 days. This is an increase of 400% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added Elicio Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 1.1 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Elicio Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

50.90% of the stock of Elicio Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

35.03% of the stock of Elicio Therapeutics is held by institutions.

Company Calendar

• Last Earnings: 8/13/2026
• Today: 10/15/2026
• Next Earnings (Estimated): 11/12/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:ELTX
• CIK: 1555192
• Web: www.angion.com
• Phone: 415-655-4899
• Fax: N/A
• Employees: N/A
• Year Founded: 2011

Price Target and Rating

• Average Price Target for Elicio Therapeutics: $15.00
• High Price Target: $23.00
• Low Price Target: $8.00
• Potential Upside/Downside: +742.7%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 6 Analysts

Profitability

• EPS (Trailing Twelve Months): ($2.17)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$39.57 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -1,266.43%
• Return on Assets: -139.94%

Debt

• Debt-to-Equity Ratio: 1.20
• Current Ratio: 2.77
• Quick Ratio: 2.77

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.09 per share
• Price / Book: 19.78

Miscellaneous

• Outstanding Shares: 27,090,000
• Free Float: 13,302,000
• Market Cap: $48.22 million
• Optionable: Not Optionable
• Beta: 1.32